DiscoverProject Oncology®Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer

Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer

Update: 2025-12-09
Share

Description

Host: Ryan Quigley




Triple-negative breast cancer (TNBC) remains one of the hardest subtypes to treat, with limited options and high relapse rates—so identifying new therapeutic targets is critical. In this AudioAbstract, Ryan Quigley spotlights research presented at the San Antonio Breast Cancer Symposium that implicates ribosome biogenesis as a key vulnerability. Tune in to learn how this approach could inform the next generation of TNBC therapies.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer

Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer